ArticleVaccine2014
Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle.
Article in Vaccine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Intranasal Immunization with a Recombinant Adenovirus Encoding Multi-Stage Antigens ofVaccines · 2024Article
- Review of Current Tuberculosis Human Infection Studies for Use in Accelerating Tuberculosis Vaccine Development: A Meeting Report.The Journal of infectious diseases · 2024Article
- A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy.PLoS biology · 2024Article
- Challenges in Developing a Controlled Human Tuberculosis Challenge Model.Current topics in microbiology and immunology · 2024Review
- Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals.Frontiers in immunology · 2024Review
- Controlled human infection models in COVID-19 and tuberculosis: current progress and future challenges.Frontiers in immunology · 2023Review
- Vaccination Strategies in a Potential Use of the Vaccine against Bovine Tuberculosis in Infected Herds.Animals : an open access journal from MDPI · 2022Review
- Role of animal models in biomedical research: a review.Laboratory animal research · 2022Review
- Association of immune responses of Zebu and Holstein-Friesian cattle and resistance to mycobacteria in a BCG challenge model.Transboundary and emerging diseases · 2021Article
- Integrating fish models in tuberculosis vaccine development.Disease models & mechanisms · 2020Review
- Controlled Human Infection Models: Is it Really Feasible to Give People Tuberculosis?American journal of respiratory and critical care medicine · 2020Article
- Animal Models of Tuberculosis Vaccine Research: An Important Component in the Fight against Tuberculosis.BioMed research international · 2020Review
- Development of a diagnostic compatible BCG vaccine against Bovine tuberculosis.Scientific reports · 2019Article
- Transposon libraries identify novel Mycobacterium bovis BCG genes involved in the dynamic interactions required for BCG to persist during in vivo passage in cattle.BMC genomics · 2019Article
- Ag85A-specific CD4Vaccine · 2018Article
- Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines.Tuberculosis (Edinburgh, Scotland) · 2018Article
- Research and development of new tuberculosis vaccines: a review.F1000Research · 2018Review
- Immune response profiles of calves following vaccination with live BCG and inactivated Mycobacterium bovis vaccine candidates.PloS one · 2017Article
- A review of clinical models for the evaluation of human TB vaccines.Human vaccines & immunotherapeutics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Vaccination is being considered as part of a sustainable strategy for the control of bovine tuberculosis (BTB) in the UK. The live attenuated Mycobacterium bovis bacillus Calmette-Guerin (BCG) has been used experimentally to vaccinate cattle against BTB. However, BCG confers partial protection against BTB and therefore, there is a need to develop improved vaccines. BTB vaccine efficacy experiments require the use of biosafety level 3 facilities which are expensive to maintain, generally oversubscribed and represent a bottle neck for the testing of vaccine candidates. One indicator of the induction of protective responses would be the ability of the host's immune response to control/kill mycobacteria. In this work we have evaluated an intranodal BCG challenge for the selection of vaccine candidates at biosafety level 2 which are capable of inducing mycobactericidal responses. To our knowledge, this is the first such report. Whilst BCG only confers partial protection, it is still the standard against which other vaccines are judged. Therefore we tested the BCG intranodal challenge in BCG (Danish strain) vaccinated cattle and showed that vaccinated cattle had lower BCG cfu counts than naïve cattle at 14 and 21 days after intranodal challenge with BCG (Tokyo strain). This model could help prioritize competing TB vaccine candidates and exploration of primary and secondary immune responses to mycobacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.